Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Infectious diseases · Vaccine · 2026-07-21
RCTn = 903
Hussain et al. Immunogenicity and reactogenicity of fractional vs. full booster doses of COVID-19 vaccines: A non-inferiority, randomized, double-blind, phase IV clinical trial in PakistanInfectious diseases · Vaccine · 2026-07-03
RCTn = 132
Depickère et al. Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trialInfectious diseases · Vaccine · 2026-06-27
RCTn = 31
Prat-Aymerich et al. A prematurely terminated phase 2, randomised trial to evaluate immunogenicity and reactogenicity of a single versus two-dose primary vaccination regimen of the mRNA vaccine BNT162b2 in previously SARS-CoV-2 infected children 5-11 years old (CoVacc trial)Infectious diseases · Lancet HIV · 2026-02-11
RCTn = 694
Govender et al. Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trialInfectious diseases · Int J Infect Dis · 2026-02-06
RCTn = 322
Stemler et al. Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults ≥75 years (EU-COVAT-1-AGED)-final reportInfectious diseases · Vaccine · 2026-02-04
Meta-analysis
Anderson et al. Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5 yearsInfectious diseases · J Infect · 2025-12-01
Clinical trialn = 281
Kelly et al. Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial